Navigation Links
Amicus Therapeutics Announces First Quarter 2011 Financial Results and Continued Progress of Development Programs
Date:5/4/2011

CRANBURY, N.J., May 4, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company at the forefront of developing therapies for rare diseases, today announced financial results for the first quarter ended March 31, 2011. The Company also highlighted recent and upcoming milestones, including an update on patient enrollment in the ongoing Phase 3 study of its lead program Amigal™ (migalastat HCl) for Fabry disease.

Development Pipeline Highlights

  • Enrollment in Phase 3 Amigal study (Study 011) is nearing completion and is expected to be fully enrolled in 2Q11 or 3Q11
  • Phase 2 Amigal extension study continues to provide encouraging safety and renal function data following up to four years of treatment
  • Patient dosing commenced in Phase 2 study of Amigal co-administered with enzyme replacement therapy (ERT) for Fabry disease
  • Moving forward with Phase 2 study of AT2220 (1-deoxynojirimycin HCI) co-administered with ERT for Pompe disease

  • Matthew R. Patterson, President and Acting Chief Executive Officer of Amicus Therapeutics said, "We continue to make excellent progress across all parts of our business. Our Phase 3 study of Amigal for Fabry disease remains our top priority and we are close to enrolling the final patient. We are also excited to have dosed our first patient in a Phase 2 study evaluating pharmacological chaperones co-administered with ERT. We see this approach as an important extension of our science and a validation of the broader therapeutic potential of our pharmacological chaperone technology. Amicus is in a position of strategic and financial strength due to the positive momentum of our development programs and the successful collaboration with our partner, GSK Rare Diseases. Our team is focused on the achievement of multiple key milestones during 2011."

    First Qua
    '/>"/>

    SOURCE Amicus Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
    2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
    3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
    4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
    5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
    6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
    7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
    8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
    9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
    10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
    11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
    (Date:1/23/2015)... More than a third of reproductive-aged women enrolled in ... insurance, filled a prescription for an opioid pain medication each ... Morbidity and Mortality Weekly Report (MMWR). Opioids ... to severe pain.  They are also found in some prescription ...
    (Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
    Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2
    ... the market leader in automated revenue integrity solutions, ... Regional Medical Center, a 235-bed non-profit medical center ... nation,s five star hospitals in community value, Kingman ... to the range of Craneware Revenue Integrity Solutions™ ...
    ... Mass., June 2, 2011 Cynosure, Inc. (NASDAQ: ... minimally invasive and non-invasive aesthetic applications, today announced that it ... 1:30 p.m. (ET) on Thursday, June 9 in New York ... CEO Michael Davin and Executive Vice President, Treasurer and CFO ...
    Cached Medicine Technology:Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 3Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 4
    (Date:1/22/2015)... (PRWEB) January 22, 2015 The City of West ... 10 a.m., to commemorate the 42nd anniversary of the Supreme Court ... , “It’s been 42 years since the Roe vs. Wade decision ... still as present as ever,” said City of West Hollywood Councilmember ...
    (Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
    (Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
    (Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
    Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
    ... Solutions, and Blue Shield of California Look to Promote ... 17 The State of California,s efforts to move ... shot in the arm today as The California Public ... Medco Health Solutions, Inc., and Blue Shield of California ...
    ... PRA ) said today that A. M. Best ... The Group,s debt rating was also upgraded to "BBB." The ... http://www.newscom.com/cgi-bin/prnh/20081024/PROASSURANCELOGO ) , ... outstanding financial performance," said W. Stancil Starnes, the President and ...
    ... TMC207 and the discovery of new drugs to treat ... new landmark collaboration between the Global Alliance for TB ... and Tibotec Inc., (Tibotec), a global pharmaceutical company, has ... response to the urgent need to accelerate the discovery ...
    ... Which Currently Dominate the Market, Will Decline by $1 ... Report from Decision Resources , , WALTHAM, Mass., ... leading research and advisory firms for pharmaceutical and healthcare ... anti-amyloid monoclonal antibodies, most notably Elan/Wyeth,s bapineuzumab and Eli ...
    ... As job loss, bankruptcy, and divorce skyrocket with the global ... to cope. The burden of these concerns can be agonizing, ... "7 Proven Steps: How to Defeat Stress Without Going Through ... many different kinds of stress life can throw your way. ...
    ... June 17 Modern technology is affecting the lives ... The unique needs of elders and their sometimes faraway ... technologies. Consider the problem of an elderly person living ... to visit the doctor or to eat a meal. ...
    Cached Medicine News:Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 2Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 3Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 4Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 5Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 6Health News:California Doctors to Get Wired in State's Largest e-Prescribing Initiative 7Health News:A. M. Best Upgrades ProAssurance Group to 'A' (Excellent) 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6Health News:New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimer's Disease Market 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 2Health News:'7 Proven Steps: How to Defeat Stress Without Going Through the Embarrassment of Counseling': Proven Ways to Defeat Stress 3Health News:New Technology Assists Independent Seniors 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: